Newsroom

Sorted by: Latest

-

LTM erweitert BlueVerse ™ Tech um AppIQ, AgentIQ und FusionIQ, um KI-gestütztes Engineering voranzutreiben

MUMBAI, Indien & WARREN, New Jersey--(BUSINESS WIRE)--LTM – der Partner für Business Creativity der weltweit größten Unternehmen – gab heute die Erweiterung von BlueVerseTM Tech, seiner KI-gesteuerten Engineering-Plattform,, durch die Einführung von AppIQ, AgentIQ und FusionIQ bekannt – drei speziell entwickelte Plattformen, die Unternehmen dabei unterstützen sollen, Anwendungen zu modernisieren, eine KI-orientierte Softwarebereitstellung zu orchestrieren und Qualität in großem Maßstab zu gewäh...
-

Zero Networks Recognized as a Leader and Outperformer in the GigaOm Radar Report for Microsegmentation

ORLANDO, Fla.--(BUSINESS WIRE)--Zero Networks, the leading provider of zero trust security solutions, today announced it has been named a Leader and Outperformer in the 2026 GigaOm Radar Report for Microsegmentation, recognizing the company’s approach to identity-based microsegmentation and automated policy generation for modern hybrid environments. Zero Networks is positioned in the Innovation/Platform Play quadrant, reflecting both the platform’s capabilities and the company’s strong developm...
-

BostonGene Advances AI-Driven Disease Modeling in Oncology in Collaboration with Leading Experts in Cancer Genomics at USCAP 115th Annual Meeting

WALTHAM, Mass.--(BUSINESS WIRE)--BostonGene, developer of the leading AI foundation model for tumor and immune biology, today announced an oral presentation at the United States and Canadian Academy of Pathology (USCAP) 115th Annual Meeting. The session highlights new clinical data generated in collaboration with leading academic investigators, including Weill Cornell Medicine. The event, held from March 21-26 at the Henry B. González Convention Center in San Antonio, TX, is the world's premier...
-

LTM amplía la tecnología BlueVerse™ con AppIQ, AgentIQ y FusionIQ para acelerar la ingeniería impulsada por la IA

BOMBAY (India) y WARREN (Nueva Jersey)--(BUSINESS WIRE)--LTM, el socio en Creatividad Empresarial de las empresas más grandes del mundo, anuncia la ampliación de BlueVerseTM Tech, su plataforma de ingeniería basada en IA, con el lanzamiento de AppIQ, AgentIQ y FusionIQ: tres plataformas diseñadas específicamente para ayudar a las empresas a modernizar sus aplicaciones, coordinar la entrega de software centrada en la IA y garantizar la calidad de la ingeniería a gran escala. A medida que el desa...
-

Amani Therapeutics Closes $25 Million Series A to Advance AM-01, a Potential Best-in-Class Therapy for Serious Neuropsychiatric Disorders

NEW YORK--(BUSINESS WIRE)--Amani Therapeutics, a newly formed biotechnology company backed by RTW Investments, today announced the closing of a $25 million Series A financing. The company also announced the appointment of its executive leadership team and the in-licensing of worldwide rights from AstraZeneca to a Phase 3–ready novel chemical entity (NCE), which is a component of Amani’s lead program, AM-01. Amani’s mission is to develop highly efficacious, safer medicines for people living with...
-

RTB House Report Reveals The New Reality of Buying: “Research-Heavy” Consumers Are Rewriting the Path to Purchase

NEW YORK--(BUSINESS WIRE)--New consumer research from RTB House reveals the research habits of different generations of American shoppers....
-

Riassunto: LTM amplia BlueVerse ™ Tech con AppIQ, AgentIQ e FusionIQ per accelerare la progettazione guidata dall'AI

MUMBAI, India e WARREN, N.J.--(BUSINESS WIRE)--LTM – il partner per la creatività aziendale delle maggiori aziende mondiali, oggi ha annunciato l'espansione di BlueVerseTM Tech, la sua piattaforma di progettazione guidata dall'AI, con il lancio di AppIQ, AgentIQ e FusionIQ — tre piattaforme realizzate appositamente per aiutare le aziende a modernizzare le applicazioni, coordinare la fornitura di software incentrata sull'AI e progettare qualità su larga scala. Lo sviluppo del software si sta evo...
-

Spear Bio Introduces New Ultra-Sensitive Neurodegenerative Assays and Expands Direct Access at AD/PD 2026

WOBURN, Mass.--(BUSINESS WIRE)--Spear Bio, an innovator in ultrasensitive protein biomarker detection, showcased three new SPEAR UltraDetect™ immunoassays—brain-derived p-Tau 217 (BD-pTau 217), α-synuclein (α-syn) and phospho-Ser129-α-synuclein (pS129-α-syn)—at the International Conference on Alzheimer’s & Parkinson’s Diseases (AD/PD 2026) last week. The product debuts coincide with the company’s newly established direct-to-customer operations in North America and Europe, an important step...
-

Samenvatting: LTM breidt BlueVerse ™ Tech uit met AppIQ, AgentIQ en FusionIQ om engineering geleid door AI te versnellen

MUMBAI, India & WARREN, N.J.--(BUSINESS WIRE)--LTM – de 'Business Creativity'-partner van de grootste ondernemingen ter wereld, kondigde vandaag de uitbreiding aan van BlueVerseTM Tech, haar engineering-platform aangestuurd door AI, met de lancering van AppIQ, AgentIQ en FusionIQ — drie specifiek gebouwde platformen ontworpen om ondernemingen te helpen applicaties te moderniseren, AI‑first softwarelevering te orkestreren en kwaliteit op schaal tot stand te brengen. Nu softwareontwikkeling evolu...
-

RapidFort Partners with Nutanix to Deliver Secure, Compliant Kubernetes at Development Speed for Enterprise AI Workloads

AMSTERDAM--(BUSINESS WIRE)--RapidFort partners with Nutanix to help enterprises scale Kubernetes for AI workloads while reducing risk, compliance burden, and operational burden....